Efficacy of anti-interleukin-2 receptor antibody (daclizumab) in reducing the incidence of acute rejection after renal transplantation

Nephro-Urology Monthly

Volumn 4, Issue 2, 2012, Pages 475-477

  Saghafi, Hossein ^a   Rahbar, Khosrow ^b   Haghighi, Ali Nobakht ^b   Qoreishi, Mohammad ^b   Safdari, Farshad ^c  

^a QOM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Daclizumab; Graft Rejection; Renal Transplantation

Indexed keywords

CYCLOSPORIN A; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ACUTE GRAFT REJECTION; ADD ON THERAPY; ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVING DONOR; LONG TERM SURVIVAL; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; POSTOPERATIVE COMPLICATION; PREDICTION; RISK REDUCTION; SEX DIFFERENCE; UNRELATED DONORS;

EID: 84858405029     PISSN: 22517006     EISSN: 22517014     Source Type: Journal    
DOI: 10.5812/numonthly.1806     Document Type: Article

References (17)

1. Danovitch GM. Handbook of kidney transplantation. 5th ed. philadelphia: Lippincott Williams & Wilkins; 2009.
2. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation. 1993;55(4):752-6; discussion 6-7.
3. Lindholm A, Ohlman S, Albrechtsen D, Tufveson G, Persson H, Persson NH. The impact of acute rejection episodes on longterm graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation. 1993;56(2):307-15.
4. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342(9):605-12.
5. Abou-Jaoude MM, Ghantous I, Almawi WY. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation. Mol Immunol. 2003;39(17-18):1083-8.
6. Ekberg H, Backman L, Tufveson G, Tyden G. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups. Transplant Proc. 1999;31(1-2):267-8.
7. Poorrezagholi F, Einollahi B, Firoozan A, Nafar M, Yadegari H, Moghaddam SM, et al. Effect of daclizumab (zenapax) on prevention of acute rejection of renal transplantation. Transplant Proc. 2003;35(7):2735-6.
8. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation. 1999;67(1):110-5.
9. Sageshima J, Ciancio G, Chen L, Burke GW, 3rd. Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation. Biologics. 2009;3:319-36.
10. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation. 1999;67(2):276-84.
11. Kandus A, Grego K, Bren AF. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients. Ther Apher Dial. 2005;9(3):262-4.
12. Bumgardner GL, Ramos E, Lin A, Vincenti F. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function. Transplantation. 2001;72(4):642-7.
13. Ekberg H, Persson NH, Kallen R, Gul-Baykurt N. Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation. Scand J Immunol. 2003;58(6):670-7.
14. Meier-Kriesche HU, Kaza H, Palekar SS, Friedman GS, Mulgaonkar SP, Ojo AO, et al. The effect of Daclizumab in a high-risk renal transplant population. Clin Transplant. 2000;14(5):509-13.
15. Millan M, Pavlakis M, Alfrey E, Salvatierra O, Dafoe D, Scandling J. A Two Dose Regimen of Daclizumab (Zenapax) in High-Risk Renal Transplant Recipients. Transplantation. 1999;67(7):S84.
16. Morris JA, Hanson JE, Steffen BJ, Chu AH, Chi-Burris KS, Gotz VP, et al. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. Clin Transplant. 2005;19(3):340-5.
17. Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, et al. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study. Transplantation. 2010;89(8):1022-7.